Trial reportOral diseases2026
Micro-Needle Assisted Transmucosal Delivery of Triamcinolone and Hyaluronic Acid for the Treatment of Oral Lichen Planus: A Randomized Clinical Trial.
Trial report in Oral diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe atrophic-erosive forms of oral lichen planus (OLP) remain a major concern as these lesions can cause a wide range of symptoms leading to reduced quality of life. Nowadays, newer possibilities are offered by micro-needles as an effective transmucosal drug delivery. The aim of this single-blinded randomized clinical trial was to determine the therapeutic efficacy of micro-needling (MN) as a novel technique for transmucosal delivery of triamcinolone acetonide (TA) and hyaluronic acid (HA) on symptomatic OLP lesions.
methodsTwenty volunteers with bilateral symptomatic OLP lesions were randomly assigned to the study involving four different treatment groups (G): G
resultsTwenty patients (40 lesions; 10 per group) were included. G
conclusionThis study uncovered the advantages of MN in promoting healing, reducing severity, and alleviating pain in OLP patients. Therefore, MN has the potential to become an effective and well-tolerated treatment modality for symptomatic OLP. Moreover, the adjunctive use of MN with topical application of both TA and HA demonstrated the most significant therapeutic benefits, suggesting a synergistic effect.
trial registrationirct.behdasht.gov.ir: IRCT20231213060357N1 (17 February 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.